
MAXIOM Launches the World's First Human-Centered AI Coach for Health & Performance
PALO ALTO, Calif.--(BUSINESS WIRE)--Today, Maxiom Labs, Inc. (MAXIOM) officially launched its revolutionary AI platform designed to optimize health, fitness, and performance—for committed athletes and everyday achievers alike. After months of development, billions of data sets, and reinforcement learning built exclusively on the most-cited, peer-reviewed science—and shaped by feedback from thousands of users—MAXIOM secured investment from Switzerland-based genetics firm DNAthlete, closed an oversubscribed $2M seed round led by Conscious Ventures, and opened its $6M Series A. The company is now entering clinical trials to demonstrate that MAXIOM can match—and ultimately outperform—human experts. Its mission: to inspire and empower the full potential of one billion people.
The world is changing — and fast. For the first time in history, advanced DNA sequencing meets adaptive artificial intelligence to create something not merely new, but transformative. This isn't a feature upgrade. This is a leap forward for humanity.
Share
Founded by experts in AI, human performance, sports science, and precision medicine, MAXIOM combines deep technical rigor with decades of real-world coaching and clinical experience.
'Inside each of us is the blueprint for the best of us—but we're drowning in noise and bad advice,' said Eric Harr, MAXIOM Co-Founder and CEO. 'This is a decades-old, multi-trillion-dollar problem. We built MAXIOM to deliver truth, precision, and simplicity—to unlock human potential at scale.'
Simplicity Is the Superpower: Just Ask Max
MAXIOM cuts through the confusion of the health and fitness world. 'Max,' your personal SmartCoach, analyzes your DNA, training, sleep, food (with 1-click logging), and even the weather—and tells you exactly what to do to optimize your day. No guesswork. Just a simple conversation with the smartest AI in health and performance.
The Central Intelligence Behind the Wearable Industry
We're long on data, short on truth. Your wearables collect numbers. Max makes it all actionable. MAXIOM integrates seamlessly with Garmin, Apple Watch, Oura, and dozens of others to deliver unified, personalized guidance in a single, intelligent feed—or an audio chat.
Key Benefits
SmartCoach AI: Take a brief survey, connect your wearables, and Max delivers hyper-precise guidance based on your biology, goals, and lifestyle.
AskMax: Just talk—Max listens, adapts and gives you smarter advice over time.
Credible Guidance: Max is trained on the most-cited, peer-reviewed science and expert inputs
MaxConnect: Share insights across families, teams, and communities
Precision Recovery: Prevent burnout and injury using HRV, training load, sleep data, and more
Biometric Integration: DNA, bloodwork, wearables, and lifestyle—synced in one complete system
AI Coaching, Record-Breaking Performances
Three World Champions—Kristian Blummenfelt, Laura Philipp, and Gustav Iden—use Max to train smarter and perform better. Blummenfelt and Iden parted ways with their longtime coach and are entirely self-coached, guided by Max.
'Max is the future,' said Olympic and World Champion Kristian Blummenfelt, who's dominating every race he enters. 'He's getting close to outperforming the world's best coaching team — but unlike them, he's with you 24/7 and knows all your data. No bias. No wasted time. Just results. This isn't a small step forward. It's changing everything.'
Use Cases
Max has answered almost one million queries—helping people at all levels measurably improve their energy, recovery, sleep, and performance.
15-year-old Turner trains with Max. His parents track his sleep, nutrition, and recovery—without nagging or guesswork. They just ask Max.
Jessica, a busy mom of three, wanted to run again. Max designed a plan to fit her schedule. She's back—faster, stronger, and more energized.
At his annual checkup, Kevin placed his phone on the doctor's desk. In seconds, Max shared a complete health snapshot—sleep, activity, nutrition, and stress. What once took 30 minutes of guesswork now takes 30 seconds, marking the future of precision medicine: faster insights, better care, and smarter performance.
What's Next
'MAXIOM's clinical trial, launching in June, will be a randomized double blind study to examine the effects of different coaching techniques that includes both human and Max's strategies,' said Dr. Judith Lambton, Fulbright Scholar and Principal Investigator.
MAXIOM is now raising a $6M Series A to scale its breakthrough platform from thousands of engaged users to millions worldwide.
Free Trial
Try MAXIOM free for 7 days —and elevate every aspect of your health and performance.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
24 minutes ago
- Bloomberg
Swiss Growth Revised Up on US Export Surge Before Trump Tariffs
Switzerland's growth spurt into 2025 was even more pronounced than initially estimated, with the economy expanding at the fastest pace in two years. Before an anticipated hit from US tariffs, gross domestic product adjusted for large sport events increased 0.8% in the first quarter, the government said Monday. That's up from the 0.7% reported in a preliminary reading and more than the revised 0.6% recorded between October and December.
Yahoo
25 minutes ago
- Yahoo
Novartis' Pluvicto shown to slow prostate cancer in earlier setting
FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage for a drug technology that the drugmaker has pioneered. The Swiss drugmaker reported a late-stage trial showed a "clinically meaningful benefit" in progression-free survival with a positive trend in overall survival in patients with metastatic prostate cancer that still responds to standard hormone therapy. Almost all of those patients ultimately progress to a form of cancer that no longer responds to hormone therapy, a setting where Pluvicto is already approved, the company added. "These data suggest using (Pluvicto) in an earlier disease setting," Novartis said, adding that this could address a significant unmet need. Novartis only provided a brief summary of trial results and said details would be presented at a medical conference and that it would likely request regulatory approval for wider use in the second half of the year. Pluvicto is part of a class of drugs that combines cell-killing radioactive particles with molecules that attach themselves to tumours, where Novartis has a leading position. The drug saw first-quarter revenue gain 20% to $371 million. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
29 minutes ago
- Business Wire
E3 Lithium Provides Progress Update for the Demonstration Facility
CALGARY, Alberta--(BUSINESS WIRE)--E3 LITHIUM LTD. (TSXV: ETL) (FSE: OW3) (OTCQX: EEMMF), 'E3', 'E3 Lithium' or the 'Company,' a leader in Canadian lithium, is pleased to provide a progress update on its Demonstration Facility ('Demo Facility'). The Demo Facility is planned to be brought on stream in three phases through the second half of 2025 and into 2026. The lithium extraction equipment comprising of the 30-column Direct Lithium Extraction (DLE) system (the '30-Column System'), as well as the purification and concentration equipment is now fully fabricated and undergoing final checks. The heart of the lithium production equipment is comprised of five separate skids, each containing a specific operation: Skids one and two host the 30-columns and the value control for the DLE system, skids 3 and 4 host the filtration and purification equipment and skid 5 houses the control center. The skids are expected to arrive and be assembled on site in the Clearwater Project area over the next six to eight weeks. E3 Lithium has also received the sorbent for the DLE columns and completed the majority of the payments for this equipment. Following arrival on site, the equipment will be assembled and undergo operational and safety checks, followed by final leak checks. Phase 1 will use brine hosted on site for the commissioning and operation of the 30-column system equipment to produce battery-grade lithium carbonate. It is expected that shortly after the drilling of the wells in Phase 2, the production well will be tied directly into the 30-column equipment and operate using a 'live' brine feed. Operation of a fully integrated system will enable E3 Lithium to optimize the process for factors such as recovery and flow rates and will provide important data for use in the design and costing of the commercial facility. The lithium carbonate produced will be used for customer interrogation and to potentially begin pre-qualification. Each phase of the Demo Facility is an important step towards validating the process technology and E3 Lithium's ability to produce battery-grade lithium carbonate from Leduc Brines at scale. The key objective of the Demo Facility is to de-risk the project design for E3 Lithium's full commercial scale Clearwater Project as the Company progresses towards completion of the Feasibility Study and securing of project financing. 'The team is very excited to see the equipment arrive on site,' commented E3 Lithium's CEO, Chris Doornbos. 'The Demo Facility will be one of the few systems of this kind globally to operate at this scale. It is a significant achievement for E3 Lithium to turn this design into a reality, and a major step forward to see it operate in the very near future.' Preparation for Phase 3 will increase as the first phase begins field operations and is expected to be installed in early 2026. ON BEHALF OF THE BOARD OF DIRECTORS Chris Doornbos, President & CEO E3 Lithium Ltd. About E3 Lithium E3 Lithium is a development company with a total of 16.2 million tonnes of lithium carbonate equivalent (LCE) Measured and Indicated 1 as well as 0.9 million tonnes LCE Inferred mineral resources 2 in Alberta and 2.5 million tonnes LCE Inferred mineral resources 3 in Saskatchewan. The Clearwater Pre-Feasibility Study outlined a 1.13 Mt LCE proven and probable mineral reserve with a pre-tax NPV8% of USD 5.2 Billion with a 29.2% IRR and an after-tax NPV8% of USD 3.7 Billion with a 24.6% IRR 1. 1: The Clearwater Project NI 43-101 Pre-Feasibility Study, effective June 20, 2024, is available on the E3 Lithium's website ( and SEDAR+ ( 2: The mineral resource NI 43-101 Technical Report for the North Rocky Property, effective October 27, 2017, identified 0.9 Mt LCE (inferred) and is available on the E3 Lithium's website ( and SEDAR+ ( 3: The mineral resource NI 43-101 Technical Report for the Estevan Lithium District, effective May 23, 2024, identified 2.5 Mt LCE (inferred) and is available on the E3 Lithium's website ( and SEDAR+ ( Unless otherwise indicated, Kevin Carroll, P. Eng., Chief Development Officer and a Qualified Person under National Instrument 43-101, has reviewed and is responsible for the technical information contained on this news release. Forward-Looking and Cautionary Statements This news release includes certain forward-looking statements as well as management's objectives, strategies, beliefs and intentions or forward-looking information within the meaning of applicable securities laws. Forward-looking statements are frequently identified by such words as 'believe', 'may', 'will', 'plan', 'expect', 'anticipate', 'estimate', 'intend', 'project', 'potential', 'possible' and similar words referring to future events and results. Forward-looking statements are based on the current opinions, expectations, estimates and assumptions of management in light of its experience, perception of historical trends, and results of the PFS, but such statements are not guarantees of future performance. In particular, this news release contains forward-looking information relating to: the estimated mineral resources and mineral resources at the Clearwater Project; expectations regarding the PFS, including statements regarding the results of the PFS and interpretations thereof; expectations concerning the Clearwater Project, including extraction, production, pretreatment, purification, volume reduction and conversion process and features and the expected outcomes thereof; the expected economic performance of the Clearwater Project, including capital costs, operating costs, water usage, land use and carbon emissions; statements regarding the Company's strategy for minimizing environmental impact and liquid waste and maximizing water reuse, with no planned tailings or waste piles; the potential for a secondary revenue stream should the Company be able to sell the calcium carbonate generated during the production of lithium hydroxide; plans and objectives of management for the Company's operations and the Clearwater Project; and the inherent hazards associated with mineral exploration and mining operations. In preparing the forward-looking information in this news release, the Company has applied several material assumptions, including, but not limited to, that any additional financing needed will be available on reasonable terms; the exchange rates for the U.S. and Canadian currencies will be consistent with the Company's expectations; that the current exploration, development, environmental and other objectives concerning the Clearwater Project can be achieved and that its other corporate activities will proceed as expected; that the current price and demand for lithium will be sustained or will improve; that general business and economic conditions will not change in a materially adverse manner and that all necessary governmental approvals for the planned activities on the Clearwater Project will be obtained in a timely manner and on acceptable terms; the continuity of the price of lithium. All forward-looking information (including future-orientated financial information) is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of mineral exploration and development, fluctuating commodity prices, the effectiveness and feasibility of emerging lithium extraction technologies which have not yet been tested or proven on a commercial scale or on the Company's brine, risks related to the availability of financing on commercially reasonable terms and the expected use of proceeds; operations and contractual obligations; changes in estimated mineral reserves or mineral resources; future prices of lithium and other metals; availability of third party contractors; availability of equipment; failure of equipment to operate as anticipated; accidents, effects of weather and other natural phenomena and other risks associated with the mineral exploration industry; the Company's lack of operating revenues; currency fluctuations; risks related to dependence on key personnel; estimates used in financial statements proving to be incorrect; competitive risks and the availability of financing, as described in more detail in our recent securities filings available under the Company's profile on SEDAR+ at Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.